# A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder

> **NCT05413187** · PHASE2 · WITHDRAWN · sponsor: **TO Pharmaceuticals**

## Conditions studied

- Autistic Disorder

## Interventions

- **DRUG:** Medical Grade Cannabis oil
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT05413187
- **Lead sponsor:** TO Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** withdrawn due to COVID-19
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05413187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05413187, "A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05413187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*